Evidence map›Paper›PMID 37934671›Full record

Observational studyRevista medica del Instituto Mexicano del Seguro Social2023

[Characteristics of patients with systemic sclerosis who develop interstitial lung disease].

Luis Daniel Fajardo-Hermosillo, Mario César Ocampo-Torres, Juan Rodríguez-Silverio

Open access · greenAbstract readEnglish AbstractObservational Study
In one paragraph

Observational study in Revista medica del Instituto Mexicano del Seguro Social, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 65% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Luis Daniel Fajardo-HermosilloInstituto Mexicano del Seguro Social, Centro Médico Nacional de Occidente, Hospital de Especialidades, Servicio de Reumatología. Guadalajara, Jalisco, México.ORCID 0000-0002-8901-8383
Mario César Ocampo-TorresInstituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, Hospital de Especialidades, Servicio de Reumatología. Ciudad de México, México.ORCID 0000-0002-5414-0346
Juan Rodríguez-SilverioInstituto Politécnico Nacional, Escuela Superior de Medicina. Ciudad de México, México.ORCID 0000-0002-8998-1196
Mexican Social Security Institute · MXInstituto Politécnico Nacional · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Systemic sclerosis associated-interstitial lung disease (SSc-ILD) show a high mortality. The factors associated SSc-ILD have shown variability in different populations. There are few studies in Mexican mestizos. Objective: To analyze the epidemiological, clinical and paraclinical factors associated with SSc-ILD. Material and methods: Cross-sectional study, where patients > 18 years of age with a diagnosis of SSc according to EULAR/ACR 2013 criteria and diagnosis of ILD by forced vital capacity (FVC) < 70% and > 5% of affected lung area on tomography were included. The strength of association of the factors for ILD was measured by odds ratio (OR) with 95% confidence intervals (95% CI). The significant variables were analyzed by multiple logistic regression with adjustment. Results: Of the 80 patients with SSc, 38 (47.5%) had ILD. Risk factors such as smoking, higher activity index, lower FVC, anti-topoisomerase I antibodies, and protective factors such as a limited SSc, early capillaroscopic pattern, and anti-centromere antibodies (ACA) were associated with ILD. In the multivariate analysis, a higher activity index with OR 4.17, (95% CI 2.01-8.65) persisted as a risk factor, while ACA with OR 0.17, (95% CI 0.03-0.85) persisted as a protective factor associated with SSc-ILD. Conclusions: A higher index of activity and ACA persisted as factors associated with SSc-ILD.

Indexed as

Lung Diseases, InterstitialScleroderma, SystemicCross-Sectional StudiesHumansLungVital CapacityAnticentromere AntibodiesAnticuerpos AnticentrómeroCross-Sectional StudiesEnfermedades Pulmonares IntersticialesEsclerodermia SistémicaEstudios TransversalesFactores de RiesgoLung Diseases, InterstitialRisk FactorsScleroderma, Systemic

Identifiers

PMID37934671
PMCPMC10730132
OpenAlexW4388500476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.